THDB(SH:600867)2015-10-26 16:00Financial Performance - Net profit attributable to shareholders increased by 77.40% to CNY 389,089,271.06 for the first nine months of the year[6]. - Operating revenue for the first nine months rose by 20.39% to CNY 1,238,803,486.12 compared to the same period last year[6]. - The weighted average return on equity increased by 7.01 percentage points to 17.45%[7]. - Basic and diluted earnings per share increased by 61.90% to CNY 0.34[7]. - Total revenue for Q3 2015 reached ¥458,497,408.12, an increase of 22.8% compared to ¥373,289,310.07 in Q3 2014[32]. - Year-to-date revenue for 2015 was ¥1,238,803,486.12, up 20.3% from ¥1,028,970,377.25 in the same period last year[32]. - Net profit for Q3 2015 was ¥126,029,049.29, representing a 80.0% increase from ¥69,972,671.76 in Q3 2014[33]. - Operating profit for the first nine months of 2015 was ¥452,881,093.82, compared to ¥250,456,590.40 in the same period of 2014, marking an increase of 80.9%[33]. - Operating profit for the first nine months of 2015 was ¥460.49 million, a 80% increase from ¥255.79 million in the same period last year[38]. - Total comprehensive income for Q3 2015 was ¥126.59 million, compared to ¥77.74 million in Q3 2014[39]. Cash Flow - The net cash flow from operating activities increased by 32.43% to CNY 170,643,549.76 year-to-date[6]. - Cash flow from operating activities for the first nine months of 2015 was ¥170.64 million, an increase from ¥128.86 million in the same period last year[42]. - Operating cash flow for the first nine months of 2015 was CNY 392,058,464.45, an increase of 34.1% compared to CNY 292,560,998.16 in the same period last year[45]. - Total cash inflow from financing activities reached CNY 633,184,587.20, up from CNY 470,899,315.00 year-on-year, representing a growth of 34.5%[46]. - The net cash flow from financing activities was negative at CNY -188,295,749.35, an improvement from CNY -359,417,267.43 in the same period last year[46]. - The cash flow from operating activities showed a strong performance, indicating robust operational efficiency and revenue generation capabilities[45]. Assets and Liabilities - Total assets increased by 15.35% to CNY 3,410,005,792.58 compared to the end of the previous year[6]. - The total assets as of September 30, 2015, amounted to ¥3,459,054,534.72, up from ¥2,996,571,011.85 at the beginning of the year[27]. - The total liabilities increased to RMB 1.06 billion from RMB 795.72 million at the beginning of the year, indicating a rise in financial obligations[25]. - Current liabilities increased to ¥705,221,042.21 from ¥420,078,031.74 at the start of the year, reflecting a 67.9% rise[28]. - The company’s long-term borrowings decreased slightly to RMB 284 million from RMB 298 million, indicating a reduction in long-term debt[25]. - The company’s equity attributable to shareholders increased to RMB 2.33 billion from RMB 2.14 billion, reflecting a growth in shareholder value[25]. Investments and Expenditures - Development expenditures increased by 35.54% to CNY 34,525,113.75 compared to the beginning of the year, indicating increased R&D efforts[13]. - The company reported a net cash outflow from investing activities of RMB 232.49 million, which was primarily due to increased investments in the construction of insulin analog production facilities[19]. - Cash outflow from investment activities totaled CNY 279,725,370.84, significantly higher than CNY 54,947,663.75 in the previous year, indicating increased investment efforts[45]. - The company reported a significant increase in prepayments, which rose to ¥191,009,388.83 from ¥35,893,576.66 at the beginning of the year[27]. - The long-term equity investment increased slightly to ¥408,913,363.25 from ¥400,029,948.94 at the start of the year[27]. Shareholder Information - The number of shareholders reached 50,501, reflecting a broadening of the shareholder base[9].